Gastritis Acute
3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Dong-A STDA-5219
Daewon PharmaDW1903
Daewon PharmaTest
Clinical Trials (3)
Total enrollment: 1,261 patients across 3 trials
Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis
Start: Jan 2024Est. completion: Jul 2025467 patients
Phase 3Completed
To Evaluate the Efficacy and Safety of DW1903 in Acute and Chronic Gastritis Patient
Start: Nov 2020Est. completion: May 2021332 patients
Phase 3Completed
To Evaluate the Efficacy and Safety of DW-1401 in Acute and Chronic Gastritis Patients
Start: Jul 2014Est. completion: Nov 2014462 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.